These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38615155)

  • 1. Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention : A report from the INVEST-STEMI group.
    Silverio A; Bellino M; Scudiero F; Attisano T; Baldi C; Catalano A; Centore M; Cesaro A; Di Maio M; Esposito L; Granata G; Maiellaro F; Muraca I; Musumeci G; Parodi G; Personeni D; Valenti R; Vecchione C; Calabrò P; Galasso G
    J Thromb Thrombolysis; 2024 Jun; 57(5):757-766. PubMed ID: 38615155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
    Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M
    Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of different doses of tirofiban combined with dual antiplatelet drugs on platelet indices, vascular endothelial function, and major adverse cardiovascular events in patients with acute ST-segment elevated myocardial infarction undergoing percutaneous coronary intervention.
    Li X; Guo X; Zhang N; Chang Y; Sun Y
    Platelets; 2024 Dec; 35(1):2402301. PubMed ID: 39324511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
    Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial).
    Bulluck H; Chong JH; Bryant J; Annathurai A; Chai P; Chan M; Chawla A; Chin CY; Chung YC; Gao F; Ho HH; Ho AFW; Hoe J; Imran SS; Lee CH; Lim B; Lim ST; Lim SH; Liew BW; Zhan Yun PL; Ong MEH; Paradies V; Pung XM; Tay JCK; Teo L; Ting BP; Wong A; Wong E; Watson T; Chan MY; Keong YK; Tan JWC; Hausenloy DJ;
    Circulation; 2024 Jul; 150(2):91-101. PubMed ID: 38742915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention.
    Ghonim AA; Mostafa A; Emara A; Algazzar AS; Qutub MA
    Cardiovasc J Afr; 2019 Sep/Oct 23; 30(5):285-289. PubMed ID: 31194213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry.
    Rigattieri S; Lettieri C; Tiberti G; Romano M; Ferlini M; Testa L; Pierini S; Ettori F; Passamonti E; Marchese A; Musumeci G; Esposito G; Tarantini G
    J Interv Cardiol; 2022; 2022():9609970. PubMed ID: 35418809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial.
    Gargiulo G; Esposito G; Cirillo P; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Avvedimento M; Tebaldi M; Wahl A; Hunziker L; Billinger M; Heg D; Windecker S; Valgimigli M
    J Cardiovasc Transl Res; 2021 Feb; 14(1):110-119. PubMed ID: 32096064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention.
    Wang H; Feng M
    Medicine (Baltimore); 2020 Jun; 99(23):e20402. PubMed ID: 32501985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention.
    Revilla-Martí P; Linares-Vicente JA; Martínez Labuena A; Jiménez Melo O; Morlanes Gracia P; Meseguer González D; Lukic A; Simó Sánchez B; Ruiz Arroyo JR
    Platelets; 2022 Feb; 33(2):265-272. PubMed ID: 33560898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
    Tang X; Li R; Zhang T
    Coron Artery Dis; 2022 Nov; 33(7):547-552. PubMed ID: 35942633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.
    Hu X; Wang W; Ye J; Lin Y; Yu B; Zhou L; Zhou Y; Dong H
    Biomed Pharmacother; 2021 Nov; 143():112196. PubMed ID: 34560551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
    Liu Y; Liu H; Hao Y; Hao Z; Geng G; Han W; Chen Q; Wang D; Liu L; Jia K; Zhou Y
    Kardiol Pol; 2017; 75(9):850-858. PubMed ID: 28612911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis.
    Venetsanos D; Sederholm Lawesson S; Alfredsson J; Janzon M; Cequier A; Chettibi M; Goodman SG; Van't Hof AW; Montalescot G; Swahn E
    BMJ Open; 2017 Sep; 7(9):e015241. PubMed ID: 28939567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial reperfusion with tirofiban injection via aspiration catheter : Efficacy and safety in STEMI patients with large thrombus burden.
    Zhang Z; Li W; Wu W; Xie Q; Li J; Zhang W; Zhang Y
    Herz; 2020 May; 45(3):280-287. PubMed ID: 29947833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effect of recombinant human pro-urokinase and tirofiban on myocardial blood flow perfusion in ST elevation myocardial infarction patients receiving primary percutaneous coronary intervention: A one-center retrospective observational study.
    Yao Z; Li W; Cheng L; Cao M; Pang Z; Li Y
    Medicine (Baltimore); 2019 Jul; 98(27):e16143. PubMed ID: 31277114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention.
    Muraca I; Pennesi M; Mattesini A; Migliorini A; Carrabba N; Virgili G; Bruscoli F; Demola P; Colombi R; Pontecorboli G; Marchionni N; Di Mario C; Valenti R
    Cardiol J; 2023; 30(4):587-594. PubMed ID: 34581427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.